Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer
使用循环 MicroRNA 进行胰腺癌的早期检测和风险评估
基本信息
- 批准号:10541824
- 负责人:
- 金额:$ 44.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AfricanAgeAlgorithmsArea Under CurveAsianBiological MarkersBloodBlood donorBlood specimenCA-19-9 AntigenCancer DetectionCancer EtiologyCell LineageCessation of lifeCodeCohort StudiesColorectal CancerCommunitiesDataDevelopmentDiagnosisDiagnosticDiseaseEarly DiagnosisEthnic PopulationEuropean ancestryGene ExpressionHispanicHumanIncidenceIndividualMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryMalignant neoplasm of pancreasMalignant neoplasm of prostateMeasuresMicroRNAsMonitorNative HawaiianNested Case-Control StudyParticipantPatientsPerformancePilot ProjectsPlasmaPlayPrimary PreventionProspective, cohort studyProteinsPublicationsRaceRegulator GenesReportingResearchResearch DesignResourcesRisk AssessmentRisk FactorsRoleSamplingScreening for cancerSecondary PreventionSurvival RateTIMP1 geneTechnologyTimeUntranslated RNAWhole BloodWomen&aposs Healthbiomarker identificationbiomarker performancecancer diagnosiscancer riskcarcinogenesiscase controlchronic pancreatitiscirculating microRNAclinical diagnosisclinical practicecohortdiagnostic biomarkerdiagnostic valueearly detection biomarkershigh risk populationindexinginnovationmale healthmicroRNA biomarkersmortalitymulti-ethnicnano-stringpancreatic cancer patientsposttranscriptionalracial populationrisk predictiontumor progression
项目摘要
Detecting pancreatic cancer at an early, asymptomatic stage is a top priority for reducing incidence and
mortality of this most fatal disease. MicroRNAs (miRNAs) regulate gene expression and play a critical role in
carcinogenesis and cancer progression. In 2014, two blood miRNA-based diagnostic indices capable of
distinguishing pancreatic cancer patients from healthy controls and chronic pancreatitis patients (AUC: 0.83 to
0.75) were reported. The utility of these indices for pancreatic cancer early detection, however, has not been
evaluated. Recently, we completed a pilot study in which we measured 800 miRNAs in pre-diagnostic plasma
samples from 185 pancreatic cancer cases and individually-matched controls selected from the Prostate, Lung,
Colorectal and Ovary Cancer Screening Trial (PLCO). We applied the algorithms of the two reported diagnostic
indices and found that one index is reasonably effective in discriminating pancreatic cancer patients from
controls within 2 years (AUC= 0.73) but not from 2- <5 years (AUC=0.68) before cancer diagnosis. The AUC
increased to 0.83 for both <2 years and 2- <5 years prior to cancer diagnosis when 4 miRNAs selected
from our own pilot study were applied as the classifier; and for <2 years, further increased to 0.92 when
CA19-9 and known risk factors were added to the classifier. To validate these highly promising findings and to
evaluate the time window during which the discriminative/predictive miRNAs are most informative for cancer
early detection and/or risk assessment, we propose a comprehensive and confirmatory study using additional
PLCO resources as well as resources from four prospective cohort studies: the Southern Community Cohort
Study (SCCS), the Multiethnic Cohort Study (MEC), the Shanghai Women's Health Study (SWHS), and the
Shanghai Men's Health Study (SMHS). Specific aims for the study are: (1) To evaluate all miRNAs showing a
significant association with pancreatic cancer risk in our pilot study and from publications in an independent set
of 341 case-control pairs using plasma collected within 5 years prior to cancer diagnosis. (2) To evaluate the
association of miRNAs replicated in Aim 1 in an independent set of 924 case-control pairs with plasma
samples collected >5 years prior to cancer diagnosis by time windows (e.g., 5-9 years and 10+ years). (3) To
develop indices for early detection (based on miRNAs showing a stronger association in the time window
closer to diagnosis) and risk assessment (based on miRNAs showing a long-term association, e.g., 5+ years
prior to cancer diagnosis) using the PLCO data and validate them using samples from the SCCS, SWHS,
SMHS and MEC. (4) To assess the added value of monitoring secular changes in levels of replicated miRNAs
for cancer early detection using repeated pre-diagnosis plasma samples from the PLCO cases and controls.
Performance of miRNA-based indices will be compared to those based on CA19-9 and TIMP1 and known risk
factors. Built upon strong pilot data and unique pre-existing resources from cohorts that include multiple ethnic
populations, this innovative study has significant potential to generate highly impactful and translatable results.
在早期、无症状阶段检测胰腺癌是降低发病率和
这是最致命的疾病。microRNAs(miRNAs)调节基因表达,在基因表达调控中发挥关键作用。
致癌作用和癌症进展。2014年,两种基于血液miRNA的诊断指标能够
将胰腺癌患者与健康对照和慢性胰腺炎患者区分开(AUC:0.83至0.85)。
0.75)。然而,这些指标用于胰腺癌早期检测的实用性尚未得到证实
评估。最近,我们完成了一项初步研究,在该研究中,我们测量了诊断前血浆中的800种miRNAs,
来自185例胰腺癌病例和个体匹配的对照的样品选自前列腺,肺,
结肠直肠癌和卵巢癌筛查试验(PLCO)。我们应用了两个报告的诊断算法
指数,并发现一个指数是合理有效的区分胰腺癌患者,
在癌症诊断前2年内(AUC= 0.73),但在癌症诊断前2- <5年(AUC=0.68),的AUC
当选择4种miRNA时,在癌症诊断前<2年和2- <5年均增加至0.83
从我们自己的试点研究中应用作为分类器;<2年,进一步增加到0.92时,
CA 19 -9和已知的危险因素被添加到分类器中。为了验证这些非常有希望的发现,
评估区分性/预测性miRNA对癌症信息量最大的时间窗
早期检测和/或风险评估,我们建议使用额外的
PLCO资源以及来自四项前瞻性队列研究的资源:南方社区队列
研究(SCCS)、多种族队列研究(MEC)、上海妇女健康研究(SWHS)和
上海男性健康研究(SMHS)。本研究的具体目的是:(1)评估所有显示出
在我们的初步研究和独立研究的出版物中,
使用癌症诊断前5年内收集的血浆的341个病例对照对。(2)评价
在一组独立的924个病例对照对中,Aim 1中复制的miRNA与血浆的相关性
通过时间窗在癌症诊断前>5年收集的样品(例如,5-9 10+年)。(3)到
开发早期检测的指标(基于在时间窗内显示更强关联的miRNA
更接近诊断)和风险评估(基于显示长期关联的miRNA,例如,5+ years
在癌症诊断之前)使用PLCO数据,并使用来自SCCS,SWHS,
SMHS和MEC。(4)评估监测复制的miRNAs水平长期变化的附加价值
使用来自PLCO病例和对照的重复诊断前血浆样品进行癌症早期检测。
基于miRNA的指标的性能将与基于CA 19 -9和TIMP 1以及已知风险的指标进行比较。
因素建立在强大的试点数据和独特的预先存在的资源,从队列,包括多个种族
这项创新研究具有产生高度影响力和可翻译结果的巨大潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VERONICA WENDY SETIAWAN其他文献
VERONICA WENDY SETIAWAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VERONICA WENDY SETIAWAN', 18)}}的其他基金
Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis
西班牙裔晚期 NAFLD 差异的机制:多层次分析
- 批准号:
10530687 - 财政年份:2021
- 资助金额:
$ 44.03万 - 项目类别:
Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis
西班牙裔晚期 NAFLD 差异的机制:多层次分析
- 批准号:
10323053 - 财政年份:2021
- 资助金额:
$ 44.03万 - 项目类别:
Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer
使用循环 MicroRNA 进行胰腺癌的早期检测和风险评估
- 批准号:
10321615 - 财政年份:2019
- 资助金额:
$ 44.03万 - 项目类别:
Understanding the Determinants of Racial/Ethnic Disparities in Liver Cancer and Chronic Liver Disease in Understudied and High-Risk Populations
了解未充分研究和高危人群中肝癌和慢性肝病的种族/民族差异的决定因素
- 批准号:
10112841 - 财政年份:2018
- 资助金额:
$ 44.03万 - 项目类别:
Contribution of Racial Disparity Towards the Early Development of Pancreatic Cancer
种族差异对胰腺癌早期发展的贡献
- 批准号:
10006120 - 财政年份:2018
- 资助金额:
$ 44.03万 - 项目类别:
Investigating the cause of racial/ethnic disparity in pancreatic cancer incidence
调查胰腺癌发病率种族/民族差异的原因
- 批准号:
9300756 - 财政年份:2017
- 资助金额:
$ 44.03万 - 项目类别:
Investigating the cause of racial/ethnic disparity in hepatocellular cancer risk
调查肝细胞癌风险中种族/民族差异的原因
- 批准号:
8829805 - 财政年份:2014
- 资助金额:
$ 44.03万 - 项目类别:
Investigating the cause of racial/ethnic disparity in hepatocellular cancer risk
调查肝细胞癌风险中种族/民族差异的原因
- 批准号:
8704088 - 财政年份:2014
- 资助金额:
$ 44.03万 - 项目类别:
Type 1 and Type 2 Endometrial Cancer: Have They Different Risk Factors? A Pooled
1 型和 2 型子宫内膜癌:它们有不同的危险因素吗?
- 批准号:
7659200 - 财政年份:2009
- 资助金额:
$ 44.03万 - 项目类别:
Type 1 and Type 2 Endometrial Cancer: Have They Different Risk Factors? A Pooled
1 型和 2 型子宫内膜癌:它们有不同的危险因素吗?
- 批准号:
7779484 - 财政年份:2009
- 资助金额:
$ 44.03万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 44.03万 - 项目类别:
Directed Grant